SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (ADMP), a biopharmaceutical company developing and marketing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, announced today that It will host an investor conference call on Monday, May 16, 2022 at 2:00 p.m. PT to discuss its financial and operating results for the first quarter of 2022 and provide an update on its business. The company’s press release regarding its first quarter 2022 financial results is expected to be available after 1:00 p.m. PT on May 16, 2022, and on its website.
Event: Adamis Pharmaceuticals First Quarter 2022 Financial Results Conference Call
When: Monday, May 16, 2022
Time: 2:00 p.m. PT (5:00 p.m. ET)
Call in the United States (toll-free): (844) 825-9789
Toll Free/International: (412) 317-5180
Conference ID: 10167229
Dennis J. Carlo, Ph.D., President and CEO of Adamis, will host the call along with other members of the leadership team. The call is open to the public and will provide an update on recent developments, events that have taken place during the year and some goals for future periods. Forward-looking statements regarding expectations regarding future business performance may be made during the conference call.
A live audio webcast of the conference call will also be available via this link, with a replay available shortly after the live event.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on the development and commercialization of products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory diseases. The company’s SYMJEPI® (epinephrine) Injectable products are FDA approved for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company’s ZIMHI™ (naloxone) injectable product is approved for the treatment of opioid overdoses. Tempol is being developed for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway. For more information about Adamis Pharmaceuticals, please visit our website and follow us on Twitter and LinkedIn.
Contact:
Adamis Investor Relations
Robert Uhl
General director
ICR Westwicke
619.228.5886
[email protected]
